UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 181

Sortiert nach

Identification of Multiple 5‑HT4 Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease

Journal of medicinal chemistry, 2012-11, Vol.55 (21), p.9240-9254

2012

Volltextzugriff (PDF)

Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor

Journal of medicinal chemistry, 2017-07, Vol.60 (13), p.5673-5698

2017

Volltextzugriff (PDF)

Building a Connection to Your Water: York Region's “Water Is” Communications Campaign

Journal - American Water Works Association, 2018-10, Vol.110 (10), p.80-85

McDowell, Laura

2018

Volltextzugriff (PDF)

Perspective on Antibacterial Lead Identification Challenges and the Role of Hypothesis-Driven Strategies

SLAS discovery, 2019-04, Vol.24 (4), p.440-456

2019

Volltextzugriff (PDF)

Characterization of substrate binding and catalysis in the potential antibacterial target N‐acetylglucosamine‐1‐phosphate uridyltransferase (GlmU)

Protein science, 2007-12, Vol.16 (12), p.2657-2666

2007

Volltextzugriff (PDF)

A novel series of [3.2.1] azabicyclic biaryl ethers as α3β4 and α6/4β4 nicotinic receptor agonists

Bioorganic & medicinal chemistry letters, 2010-08, Vol.20 (16), p.4749-4752

2010

Volltextzugriff (PDF)

Particle transport through porous media

Water resources research, 1986-12, Vol.22 (13), p.1901-1921

1986

Volltextzugriff (PDF)

Chemical mobilization of micron-sized particles in saturated porous media under steady flow conditions

Environmental science & technology, 1992-03, Vol.26 (3), p.586-593

McDowell-Boyer, Laura M

1992

Volltextzugriff (PDF)

Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline

Journal of medicinal chemistry, 2018-10, Vol.61 (20), p.9360-9370

2018

Volltextzugriff (PDF)

Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of κB Kinase ɛ and Inflammatory Cross-talk with Macrophages

The Journal of biological chemistry, 2017-01, Vol.292 (1), p.339-350

2017

Volltextzugriff (PDF)

Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1260-1260

2021

Volltextzugriff (PDF)

Cloning and Functional Characterization of an NAD+-Dependent DNA Ligase from Staphylococcus aureus

Journal of Bacteriology, 2001-05, Vol.183 (10), p.3016-3024

2001

Volltextzugriff (PDF)

Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of κB Kinase ϵ and Inflammatory Cross-talk with Macrophages

The Journal of biological chemistry, 2017-01, Vol.292 (1), p.339-350

2017

Volltextzugriff (PDF)

Abstract 1273: Discovery of a potent, selective, and orally bioavailable SOS1 inhibitor, RMC-023, an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1273-1273

2021

Volltextzugriff (PDF)

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate

Journal of medicinal chemistry, 2018-02, Vol.61 (3), p.1001-1018

2018

Volltextzugriff (PDF)

Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors

Journal of medicinal chemistry, 2012-11, Vol.55 (21), p.9055-9068

2012

Volltextzugriff (PDF)

Structure of a small‐molecule inhibitor complexed with GlmU from Haemophilus influenzae reveals an allosteric binding site

Protein science, 2008-03, Vol.17 (3), p.577-582

2008

Volltextzugriff (PDF)

Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.526-526

2023

Volltextzugriff (PDF)

Abstract 1598: RM-046, a first-in-class, mutant-selective, and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1598-1598

2023

Volltextzugriff (PDF)

Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia

Journal of medicinal chemistry, 2011-07, Vol.54 (13), p.4536-4547

2011

Volltextzugriff (PDF)

Abstract 3596: RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3596-3596

2022

Volltextzugriff (PDF)

Correction to Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor

Journal of medicinal chemistry, 2018-04, Vol.61 (8), p.3753-3753

2018

Volltextzugriff (PDF)

Identification of Multiple 5-HT 4 Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease

Journal of medicinal chemistry, 2012-11, Vol.55 (21), p.9240-9254

2012

Volltextzugriff (PDF)

P4‐188: ORL1: A Novel Mechanism with Potential to Provide Beneficial Effects for Depressive Symptoms Associated With Alzheimer's Disease (AD)

Alzheimer's & dementia, 2011-07, Vol.7 (4S_Part_22), p.S769-S769

2011

Volltextzugriff (PDF)

ORL1: A Novel Mechanism With Potential to Provide Beneficial Effects for Depressive Symptoms Associated With Alzheimer's Disease (AD)

Alzheimer's & dementia, 2011-07, Vol.7 (4), p.S769-S769

2011

Volltextzugriff (PDF)

1 – 25 von 181

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(163)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(180)
Japanisch
(24)

Erscheinungsjahr

n.n

Thema

Science & Technology
(100)
Life Sciences & Biomedicine
(85)
Humans
(57)
Female
(29)
Male
(23)
Animals
(19)
Environmental Sciences
(14)
Physical Sciences
(14)
Biochemistry & Molecular Biology
(13)
Adult
(12)
Environmental Sciences & Ecology
(12)
Pharmacology & Pharmacy
(12)
Science & Technology - Other Topics
(11)
Mice
(10)
Social Sciences
(10)
Technology
(10)
Chemistry, Medicinal
(9)
Middle Aged
(9)
Molecular Sequence Data
(9)
Multidisciplinary Sciences
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Identification of Multiple 5‑HT4 Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease

Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor

Building a Connection to Your Water: York Region's “Water Is” Communications Campaign

Perspective on Antibacterial Lead Identification Challenges and the Role of Hypothesis-Driven Strategies

Characterization of substrate binding and catalysis in the potential antibacterial target N‐acetylglucosamine‐1‐phosphate uridyltransferase (GlmU)

A novel series of [3.2.1] azabicyclic biaryl ethers as α3β4 and α6/4β4 nicotinic receptor agonists

Particle transport through porous media

Chemical mobilization of micron-sized particles in saturated porous media under steady flow conditions

Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline

Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of κB Kinase ɛ and Inflammatory Cross-talk with Macrophages

Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers

Cloning and Functional Characterization of an NAD+-Dependent DNA Ligase from Staphylococcus aureus

Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of κB Kinase ϵ and Inflammatory Cross-talk with Macrophages

Abstract 1273: Discovery of a potent, selective, and orally bioavailable SOS1 inhibitor, RMC-023, an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate

Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors

Structure of a small‐molecule inhibitor complexed with GlmU from Haemophilus influenzae reveals an allosteric binding site

Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers

Abstract 1598: RM-046, a first-in-class, mutant-selective, and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target

Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia

Abstract 3596: RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models

Correction to Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor

Identification of Multiple 5-HT 4 Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease

P4‐188: ORL1: A Novel Mechanism with Potential to Provide Beneficial Effects for Depressive Symptoms Associated With Alzheimer's Disease (AD)

ORL1: A Novel Mechanism With Potential to Provide Beneficial Effects for Depressive Symptoms Associated With Alzheimer's Disease (AD)

Suchergebnisse filtern